Sino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis

Sino Biopharmaceutical Limited has enrolled the first patient in the Phase III trial of TDI01, a selective ROCK2 inhibitor for idiopathic pulmonary fibrosis (IPF). This is the first global Phase III trial for a ROCK2 inhibitor targeting IPF. TDI01 aims to address issues like vascular leakage and inflammation associated with IPF, with the goal of providing a safer treatment option. No scientific results have been shared yet; the announcement focuses on clinical development progress.